Flavonoids

Compound Class	Flavonoids — C6-C3-C6 polyphenolic backbone class comprising flavonols, flavones, flavanones, and related subclasses
Representative Members	Vitexin, hyperoside, rutin (hawthorn); isorhamnetin glycosides (sea buckthorn); quercetin glycosides (lotus leaf)
Botanical Sources	Crataegus monogyna (hawthorn), Hippophae rhamnoides (sea buckthorn), Nelumbo nucifera (lotus leaf)
Plant Part(s)	Leaf and flower (hawthorn), berry (sea buckthorn), leaf (lotus)
Typical Standardisation	Total flavonoids by aluminium-chloride colorimetric assay, expressed as rutin or quercetin equivalents; 2–10% common commercial range
Primary Applications	Cardiovascular support (hawthorn), general antioxidant/skin-health positioning (sea buckthorn), weight-management formulation (lotus leaf)
Claim Strength (Overview)	Moderate for hawthorn cardiovascular endpoints (Cochrane-reviewed); Emerging for sea buckthorn and lotus leaf flavonoid-specific claims
Buy from Herbuno	Flavonoids 10% Powder (Sea Buckthorn Extract) | Standardized Hippophae rhamnoides → Flavonoids 2% Powder (Hawthorn Extract) | Standardized Crataegus monogyna →

Name origin: Flavonoid derives from the Latin flavus (yellow), reflecting the yellow colour of many early-isolated members of this compound class, even though the class as later defined came to include colourless, red, and blue-pigmented compounds (the latter being the anthocyanins, a flavonoid subclass documented separately in this index). Traditional use: Hawthorn (Crataegus spp.) has one of the longest continuous cardiac-tonic traditions in Western herbal medicine, used across European folk practice for centuries and formally recognised in the German Commission E monographs for heart failure classes I and II; sea buckthorn has deep roots in Tibetan, Mongolian, and Russian traditional medicine as a general restorative and wound-healing berry; lotus leaf occupies a distinct role in Traditional Chinese Medicine, historically used for its cooling and diuretic properties and, more recently, repositioned commercially around weight-management formulation. Research trajectory: Hawthorn flavonoid research matured earliest and most thoroughly among this trio, progressing through 20th-century German phytopharmaceutical development (the WS 1442 standardized extract) into large placebo-controlled cardiovascular trials; sea buckthorn and lotus leaf flavonoid research remains comparatively earlier-stage, concentrated more heavily in preclinical and observational literature. Commercial source: Hawthorn leaf-and-flower extract is the most clinically substantiated flavonoid-class ingredient in this trio and the appropriate default for cardiovascular-support positioning; sea buckthorn and lotus leaf extracts serve broader antioxidant and metabolic-support formulation roles with a thinner flavonoid-specific evidence base.

---

Evidence for Flavonoids Applications

Hawthorn extract carries the most rigorously reviewed clinical evidence of any flavonoid-class botanical in the HerbIQ index. A Cochrane systematic review examining double-blind, placebo-controlled randomized trials of hawthorn extract as an adjunctive treatment for chronic heart failure found consistent, statistically significant benefit in symptom control and physiologic outcomes, with adverse events reported as infrequent, mild, and transient (nausea, dizziness, and gastrointestinal complaints being the most common) (Cochrane Review). Cochrane reviews apply a notably conservative evidentiary standard, so this finding carries substantial weight, though the reviewed trials generally used hawthorn as adjunctive rather than standalone therapy alongside conventional heart-failure medication, a distinction that should be preserved in any formulator-facing claim. Claim strength: Moderate.

A more recent meta-analysis of randomized, placebo-controlled trials specifically examining hawthorn's effect on blood pressure in hypertensive populations found a statistically significant reduction in systolic blood pressure of approximately 6.65 mmHg across six pooled studies totalling 428 participants, with treatment periods ranging from ten weeks to six months (Szikora 2025). The diastolic blood pressure reduction in the same analysis did not reach statistical significance, an important nuance distinguishing hawthorn's systolic-predominant antihypertensive signal from its more consistently supported heart-failure symptom benefit. Claim strength: Moderate.

Hawthorn's active-constituent picture is genuinely multi-compound rather than attributable to flavonoids alone: standardized extracts such as WS 1442 are characterized simultaneously for oligomeric procyanidin (OPC) content and for flavonoid content (including hyperoside, vitexin-rhamnoside, rutin, and vitexin), with the pharmacological literature generally treating these as acting in combination rather than isolating the flavonoid fraction's independent contribution. Formulators should therefore treat "Flavonoids X%" as one component of a fuller hawthorn standardization specification rather than the sole active-marker figure. Claim strength: Moderate.

Sea buckthorn flavonoids (principally isorhamnetin glycosides) are supported by a considerably thinner clinical evidence base than hawthorn, with most available human data concentrated on the berry's broader nutrient and fatty-acid profile (sea buckthorn oil is separately notable for its unusual omega-7 palmitoleic acid content) rather than isolating the flavonoid fraction's independent cardiovascular or dermatological contribution. Positioning claims for sea buckthorn flavonoid extract should accordingly favour general antioxidant-support language over specific cardiovascular claims. Claim strength: Emerging.

Lotus leaf flavonoids have attracted commercial interest for weight-management formulation, largely on the strength of preclinical work suggesting lipid-metabolism-modulating activity of the leaf's quercetin-glycoside-rich extract, but this application currently lacks the volume of human randomized-trial data available for hawthorn's cardiovascular indication, and claims should be scoped accordingly to reflect the earlier stage of the supporting evidence. Claim strength: Emerging.

---

Dosage & Formulator Specification

Herbuno carries flavonoid-standardized extracts from hawthorn (2%, assayed against a rutin or vitexin reference standard), sea buckthorn (10%), and lotus leaf/flower material, alongside a general (unstandardized) hawthorn dry extract for formulators who prefer to specify the fuller OPC-plus-flavonoid combination rather than flavonoids in isolation. The flavonoid-percentage figure should be understood as one marker within hawthorn's broader multi-compound standardization rather than a complete potency specification on its own.

Clinical trial dosing for hawthorn in the cardiovascular literature has centred on standardized extracts (most commonly WS 1442) at approximately 900 mg/day, or lower doses such as 600 mg/day in some hypertension-focused trials, generally sustained for periods of 8 weeks to 24 months depending on the endpoint studied. Formulators should reference the specific standardized extract's OPC and flavonoid content when translating these clinical doses into a finished-product specification, since dose equivalence is defined by the extract's full marker-compound profile rather than raw plant material weight alone.

Analytical verification for hawthorn should include both total flavonoid content (aluminium-chloride colorimetric method, rutin or quercetin equivalents) and, ideally, oligomeric procyanidin content, given the compound's documented role alongside flavonoids in the extract's overall pharmacological activity. Sea buckthorn and lotus leaf extracts should be verified for total flavonoid content by the same colorimetric method, with HPLC confirmation of the dominant marker compound (isorhamnetin glycosides for sea buckthorn, quercetin glycosides for lotus).

Hawthorn is generally well tolerated at studied dosage ranges, with mild and transient gastrointestinal or dizziness-type effects being the most commonly reported adverse events in the clinical trial literature; because hawthorn is most commonly studied as an adjunct to conventional cardiovascular medication, formulators should apply standard caution language regarding concurrent use with prescription cardiac medications rather than positioning it as a standalone replacement therapy. Sea buckthorn and lotus leaf extracts carry no major safety signal in the available literature at typical dietary-supplement intakes.

---

Frequently Asked Questions — Flavonoids

Is hawthorn's cardiovascular benefit attributable to flavonoids alone?
No. Standardized hawthorn extracts are characterized for both oligomeric procyanidin (OPC) content and flavonoid content (including hyperoside, vitexin-rhamnoside, rutin, and vitexin), and the pharmacological literature generally treats these as acting together. A flavonoid percentage on a label reflects one marker within a broader multi-compound standardization.

How strong is the clinical evidence for hawthorn and heart failure?
It is among the better-reviewed botanical cardiovascular applications: a Cochrane systematic review of double-blind, placebo-controlled randomized trials found consistent benefit in symptom control and physiologic outcomes when hawthorn was used as an adjunctive treatment alongside conventional heart failure therapy, with a favourable safety profile.

Do sea buckthorn and lotus leaf flavonoids have the same evidence base as hawthorn?
No. Both carry considerably thinner clinical evidence specific to their flavonoid fraction compared to hawthorn. Sea buckthorn's better-studied bioactivity centres more on its fatty acid profile, and lotus leaf flavonoid research for weight-management applications remains largely preclinical, so claims for these two should be scoped more conservatively.

Can hawthorn flavonoid extract be taken alongside heart medication?
Most clinical trials studied hawthorn as an adjunctive therapy used alongside, not in place of, conventional cardiovascular medication, and mild interactions are possible given hawthorn's cardiac-active mechanism. Standard caution language regarding concurrent prescription cardiac medication use is appropriate for any finished product carrying a cardiovascular-support claim.

Related compounds: Quercetin, Rutin, Hesperidin, Vitexin

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery